Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Th17 response and inflammatory autoimmune diseases.

Waite JC, Skokos D.

Int J Inflam. 2012;2012:819467. doi: 10.1155/2012/819467. Epub 2011 Nov 15.

2.

Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions.

Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P.

Autoimmun Rev. 2014 Nov;13(11):1149-59. doi: 10.1016/j.autrev.2014.08.032. Epub 2014 Aug 27. Review.

PMID:
25183244
3.

Adult-onset Still's disease.

Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P.

Autoimmun Rev. 2014 Jul;13(7):708-22. doi: 10.1016/j.autrev.2014.01.058. Epub 2014 Mar 19. Review.

4.

Current perspectives on the role of IL-17 in autoimmune disease.

Yamada H.

J Inflamm Res. 2010;3:33-44. Epub 2010 Jun 18.

5.

Targeting Th17 cells in autoimmune diseases.

Yang J, Sundrud MS, Skepner J, Yamagata T.

Trends Pharmacol Sci. 2014 Oct;35(10):493-500. doi: 10.1016/j.tips.2014.07.006. Epub 2014 Aug 14. Review.

PMID:
25131183
6.

Fenofibrate inhibited the differentiation of T helper 17 cells in vitro.

Zhou Z, Sun W, Liang Y, Gao Y, Kong W, Guan Y, Feng J, Wang X.

PPAR Res. 2012;2012:145654. doi: 10.1155/2012/145654. Epub 2012 Jun 20.

8.

IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.

Mitra A, Raychaudhuri SK, Raychaudhuri SP.

Actas Dermosifiliogr. 2014 Oct;105 Suppl 1:21-33. doi: 10.1016/S0001-7310(14)70015-8. Review.

PMID:
25398489
9.

A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6.

Kadavath S, Zapantis E, Zolty R, Efthimiou P.

Int J Rheum Dis. 2014 Mar;17(3):336-40. doi: 10.1111/1756-185X.12324. Epub 2014 Feb 28. Review.

PMID:
24581387
10.

Adult-onset Still's disease: Advances in the treatment.

Castañeda S, Blanco R, González-Gay MA.

Best Pract Res Clin Rheumatol. 2016 Apr;30(2):222-238. doi: 10.1016/j.berh.2016.08.003. Epub 2016 Oct 5. Review.

PMID:
27886796
11.
12.

Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions.

Patel DD, Kuchroo VK.

Immunity. 2015 Dec 15;43(6):1040-51. doi: 10.1016/j.immuni.2015.12.003. Review.

13.

Anti-Interleukin-1 Agents in Adult Onset Still's Disease.

Giampietro C, Fautrel B.

Int J Inflam. 2012;2012:317820. doi: 10.1155/2012/317820. Epub 2012 Apr 29.

14.

Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.

Guo C, Hu F, Yi H, Feng Z, Li C, Shi L, Li Y, Liu H, Yu X, Wang H, Li J, Li Z, Wang XY.

Ann Rheum Dis. 2016 Jan;75(1):278-85. doi: 10.1136/annrheumdis-2014-205508. Epub 2014 Nov 4.

15.

The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.

Toussirot E.

Inflamm Allergy Drug Targets. 2012 Apr;11(2):159-68. Review.

PMID:
22280236
16.

Psoriasis and other Th17-mediated skin diseases.

Tokura Y, Mori T, Hino R.

J UOEH. 2010 Dec 1;32(4):317-28. Review.

PMID:
21226422
17.

[Current concepts on the physiopathology of adult-onset Still's disease].

Arlet JB, Le Thi Huong DB, Pouchot J, Piette JC.

Rev Med Interne. 2005 Jul;26(7):549-56. Epub 2004 Dec 25. Review. French.

PMID:
15996569
18.

The Interleukin (IL)-23/T helper (Th)17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Hiltensperger M, Korn T.

Cold Spring Harb Perspect Med. 2018 Jan 2;8(1). pii: a029637. doi: 10.1101/cshperspect.a029637. Review.

PMID:
29101111
19.

Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.

Wu D, Wang J, Pae M, Meydani SN.

Mol Aspects Med. 2012 Feb;33(1):107-18. doi: 10.1016/j.mam.2011.10.001. Epub 2011 Oct 14. Review.

PMID:
22020144
20.

Emerging role of interleukin-22 in autoimmune diseases.

Pan HF, Li XP, Zheng SG, Ye DQ.

Cytokine Growth Factor Rev. 2013 Feb;24(1):51-7. doi: 10.1016/j.cytogfr.2012.07.002. Epub 2012 Aug 18. Review.

Supplemental Content

Support Center